Search Results - "BALCERZAK, Stanley P"

Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms by Sandor, Victor, Bakke, Susan, Robey, Robert W, Kang, Min H, Blagosklonny, Mikhail V, Bender, Jonathon, Brooks, Rebecca, Piekarz, Richard L, Tucker, Eben, Figg, William D, Chan, Kenneth K, Goldspiel, Barry, Fojo, Antonio Tito, Balcerzak, Stanley P, Bates, Susan E

“…Purpose: The primary objectives of this trial were to define the maximum tolerated dose (MTD) and to characterize the toxicities and pharmacokinetics of…”
Get full text

Health Status and Quality of Life in Patients With Early-Stage Hodgkin’s Disease Treated on Southwest Oncology Group Study 9133 by GANZ, Patricia A, MOINPOUR, Carol M, FISHER, Richard I, PAULER, Donna K, KORNBLITH, Alice B, GAYNOR, Ellen R, BALCERZAK, Stanley P, GATTI, Gretchen S, ERBA, Harry P, MCCOY, Sheryl, PRESS, Oliver W

“…We describe the short and intermediate-term quality-of-life (QOL) outcomes in patients treated on a randomized clinical trial in early-stage Hodgkin's disease…”
Get full text

A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors by BEKAII-SAAB, Tanios S, JING LIU, CHAN, Kenneth K, BALCERZAK, Stanley P, IVY, Percy S, GREVER, Michael R, KRAUT, Eric H

“…Purpose: Oxaliplatin and paclitaxel are widely used in treating solid tumors. We designed a phase I study with the purpose of determining the maximal tolerated…”
Get full text

Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501 by VELASQUEZ, William S, LEW, Danika, GROGAN, Thomas M, SPIRIDONIDIS, C. Harris, BALCERZAK, Stanley P, DAKHIL, Shaker R, MILLER, Thomas P, LANIER, Keith S, CHAPMAN, Robert A, FISHER, Richard I

“…To determine the efficacy of combination fludarabine and mitoxantrone (FN) in untreated stages III and IV low-grade lymphoma. The major end point was to…”
Get full text

Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study by GAYNOR, Ellen R, UNGER, Joseph M, MILLER, Thomas P, GROGAN, Thomas M, WHITE, Leonard A, MILLS, Glenn M, BALCERZAK, Stanley P, VARTERASIAN, Mary, LEBLANC, Michael, FISHER, Richard I

“…Two phase II studies were conducted to evaluate infusional cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy, termed the CVAD regimen,…”
Get full text

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia by Marcucci, Guido, Byrd, John C., Dai, Guowei, Klisovic, Marko I., Kourlas, Peter J., Young, Donn C., Cataland, Spero R., Fisher, Diane B., Lucas, David, Chan, Kenneth K., Porcu, Pierluigi, Lin, Zhong-Pin, Farag, Sherif F., Frankel, Stanley R., Zwiebel, James A., Kraut, Eric H., Balcerzak, Stanley P., Bloomfield, Clara D., Grever, Michael R., Caligiuri, Michael A.

“…Overexpression of Bcl-2 is a potential mechanism for chemoresistance in acute leukemia and has been associated with unfavorable clinical outcome. We…”
Get full text

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study by Anderson, Jeanne E., Kopecky, Kenneth J., Willman, Cheryl L., Head, David, O’Donnell, Margaret R., Luthardt, Frederick W., Norwood, Thomas H., Chen, I-Ming, Balcerzak, Stanley P., Johnson, David B., Appelbaum, Frederick R.

“…Complete remission and long-term survival rates are low for older adults treated for acute myeloid leukemia (AML). Because of favorable phase 2 data using…”
Get full text

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500) by Petersdorf, Stephen H., Rankin, Cathryn, Head, David R., Terebelo, Howard R., Willman, Cheryl L., Balcerzak, Stanley P., Karnad, Anand B., Dakhil, Shaker R., Appelbaum, Frederick R.

“…Induction therapy for acute myeloid leukemia (AML) usually consists of 7 days of cytarabine at 100–200 mg/m2/day and an anthracycline. Such combinations…”
Get full text

Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin’s Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809 by Fisher, Richard I., Dana, Bruce W., LeBlanc, Michael, Kjeldsberg, Carl, Forman, Jeffrey D., Unger, Joseph M., Balcerzak, Stanley P., Gaynor, Ellen R., Roy, Vivek, Miller, Thomas

“…PURPOSE: S8809 is a randomized phase III trial determining whether intensive cytoreductive treatment, followed by interferon consolidation at the time of…”
Get full text

Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study by Hussain, M H, Glass, T R, Forman, J, Sakr, W, Smith, D C, Al-Sarraf, M, Jones, J, Balcerzak, S P, Crawford, E D, Grossman, H B

“…Patients with locally advanced bladder cancer or who are not medically fit for surgery are a therapeutic dilemma. Radiotherapy with or without single agent…”
Get more information

A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer by LYMAN, Gary H, GREEN, Stephanie J, RAVDIN, Peter M, GEYER, Charles E, RUSSELL, Christy A, BALCERZAK, Stanley P, BUDD, G. Thomas, MARTINO, Silvana

“…To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two…”
Get full text

High-dose ifosfamide with mesna and granuloctye-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma: A Southwest Oncology Group Study by TALBOT, Susan M, RANKIN, Cathryn, TAUB, Robert N, BALCERZAK, Stanley P, BHOOPALAM, Nirmala, CHAPMAN, Robert A, BAKER, Laurence H, MIDDLEMAN, Edward L, ANTMAN, Karen H

“…Abstract BACKGROUND The current study was conducted to assess the activity and toxicity of high‐dose ifosfamide and mesna with recombinant human…”
Get full text

Effects of corticosteroid therapy on human monocyte function by Rinehart, J J, Sagone, A L, Balcerzak, S P, Ackerman, G A, LoBuglio, A F

“…Since high-dose corticosteroid therapy appears to impair cellular defense mechanisms, this study examined its effect on human monocyte function. Fifteen normal…”
Get more information

A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study by Whitehead, Robert P, Benedetti, Jacqueline K, Abbruzzese, James L, Ardalan, Bach, Williamson, Stephen, Gaynor, Ellen R, Balcerzak, Stanley P, Macdonald, John S

“…The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in…”
Get full text

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study by Whitehead, Robert P, Benedetti, Jacqueline K, Abbruzzese, James L, Ardalan, Bach, Goodwin, J Wendall, Balcerzak, Stanley P, Samlowski, Wolfram E, Lenz, Heinz-Josef, Macdonald, John S

“…The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in…”
Get full text

A Phase II Study of CI-980 in Previously Untreated Extensive Small Cell Lung Cancer: An Ohio State University Phase II Research Consortium Study by Thomas, Jason P., Moore, Timothy, Kraut, Eric H., Balcerzak, Stanley P., Galloway, Sharon, Vandre, Dale D.

“…CI-980, {ethyl (S)-(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b] pyrazine-7-yl) carbamate 2-hydroxyethansulfonate (1:1)}, is a water-soluble mitotic…”
Get full text

A Phase II Study of Topotecan in Non-Hodgkin's Lymphoma: An Ohio State University Phase II Research Consortium Study by Kraut, Eric H., Balcerzak, Stanley P., Young, Donn, Davis, Mellar P., Jacobs, Samuel A.

“…Purpose: This multicenter phase II trial evaluated the efficacy and toxicity of the topoisomerase I inhibitor topotecan (TPT,…”
Get full text

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma by Talbot, Susan M, Rankin, Cathryn, Taub, Robert N, Balcerzak, Jr, Stanley P, Bhoopalam, Nirmala, Chapman, Robert A, Baker, Laurence H, Middleman, Edward L, Antman, Karen H

“…The current study was conducted to assess the activity and toxicity of high-dose ifosfamide and mesna with recombinant human granulocyte-colony-stimulating…”
Get full text

Phase II trial of topotecan in advanced gastric cancer : A Southwest Oncology Group study by BENEDETTI, J. K, BURRIS, H. A, BALCERZAK, S. P, MACDONALD, J. S

“…Topotecan (NSC 609099) is a camptothecin analogue that demonstrated activity against a variety of human tumors in preclinical studies. A phase II trial was…”
Get full text

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study by Wozniak, A J, Crowley, J J, Balcerzak, S P, Weiss, G R, Spiridonidis, C H, Baker, L H, Albain, K S, Kelly, K, Taylor, S A, Gandara, D R, Livingston, R B

“…Cisplatin has played a major role in the treatment of non-small-cell lung cancer (NSCLC). This randomized trial was performed by the Southwest Oncology Group…”
Get more information